Therapeutic Hepatitis B Vaccine (Mimogen-based) Joint Entecavir in Treating Chronic Hepatitis B Patients

Inclusion Criteria: 1. Aged 18-65 years, male or female; 2. Conforming to diagnosis standard of chronic hepatitis B according to " 2005 Guideline for Prevention and Treatment of Hepatitis B " , (with positive HBsAg for more than 6 months), never have systemic treatment of anti-HBV viral ,and * HBV-DNA ≥ 1.72×10\^4 IU/ml； * HBeAg (+), HBeAb (-)； * ALT within 2 to 10 times of ULN (upper limits of normal); 3. HLA-A2 positive; 4. Compensatory liver disease having following hematological and biochemical parameters: * WBC ≥ 3.5×10\^9/L; * ANC ≥ 1.5×10\^9/L; * PLT ≥ 80×10\^9/L; * Hb ≥ 100g/L; * TBil ≤ 1.5 ULN; * ALB not lower than low limit of normal value; * BUN no more than high limit of normal value; * Cr ≤ 1.5 ULN high limit of normal value; * PT elongation ≤ 3 sec, APTT in normal value; * Fasting blood glucose ≤ 7.0mmol/L; 5. TSH in normal value; 6. AFP test result no more than high limit of normal value; 7. Take effective contraception for subject with child-bearing potential (including females and female partners of males); 8. Understand and sign ICF approved by EC; 9. Willing to comply with the study procedures and complete the study. Exclusion Criteria: 1. Antibodies of HCV, HDV or HIV is positive; 2. ANA titer \> 1:100; 3. Decompensated liver disease (such as gullet and pylorus varicose veins, hepatic encephalopathy); 4. Have the following illness or with severe disease inappropriate to participate in the study in the view of the investigator, in cardiovascular system: instable or significant cardiovascular illness such as angina pectoris, heart attack of myocardial infarction, congestive heart failure, severe hypertension, significant arrhythmia or abnormal ECG etc; * Respiratory system: bronchiectasia, bronchial asthma, chronic obstructive pulmonary disease, respiratory failure, etc; * Endocrine, metabolism diseases: diabetes mellitus, uncontrolled thyroid diseases, etc; * Others: autoimmune disorder, active tuberculosis, malignancies (e.g.: tumor), neuropathic, metal, acute or chronic pancreatitis illness history, etc. 5. Have used anti-HBV drug ( Interferon, Lamivudine, Adefovir Dipivoxil, Entecavir and Telbivudine ) and immunomodulator ( Thymic peptide, etc ) to the administration of study medication; 6. Have allergic diathesis or have suspected allergy to εPA-44; 7. Female in pregnancy, lactation or those who plan to pregnancy during the course of the study; 8. Have history of alcohol abuse (Alcohol consumption for more than 5 years, with daily consumption over 40g for males and over 20g for females) and known drug dependence; 9. Have history of organ transplantation (except corneal transplantation and hair transplantation); 10. Have participated in any other drug clinical investigations within 3 months; 11. Any other factors inappropriate for enroll in the study or study completion in the view of the investigator.